BridgeBio Pharma Financials

BBIO Stock  USD 28.54  0.77  2.77%   
Based on the key measurements obtained from BridgeBio Pharma's financial statements, BridgeBio Pharma may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, BridgeBio Pharma's Other Assets are very stable compared to the past year. As of the 24th of December 2024, Cash And Short Term Investments is likely to grow to about 528.5 M, while Other Current Liabilities is likely to drop about 70.1 M. Key indicators impacting BridgeBio Pharma's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio3.153.3202
Notably Down
Slightly volatile
Investors should never underestimate BridgeBio Pharma's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BridgeBio Pharma's cash flow, debt, and profitability to make informed and accurate decisions about investing in BridgeBio Pharma.

Net Income

(611.04 Million)

  
Understanding current and past BridgeBio Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BridgeBio Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in BridgeBio Pharma's assets may result in an increase in income on the income statement.

BridgeBio Pharma Stock Summary

BridgeBio Pharma competes with Fate Therapeutics, Caribou Biosciences, Arcus Biosciences, Karyopharm Therapeutics, and X4 Pharmaceuticals. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 576 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS10806X1028
CUSIP10806X102
LocationCalifornia; U.S.A
Business Address3160 Porter Drive,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitebridgebio.com
Phone650 391 9740
CurrencyUSD - US Dollar

BridgeBio Pharma Key Financial Ratios

BridgeBio Pharma Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets631.7M703.6M1.0B623.0M546.4M641.2M
Other Current Liab4.1M81.5M118.2M98.0M118.8M70.1M
Other Liab3.5M7.9M22.1M26.6M30.6M32.2M
Net Tangible Assets408.5M59.5M(915.3M)(1.3B)(1.2B)(1.1B)
Net Debt(264.0M)139.7M1.3B1.3B1.4B1.4B
Retained Earnings(440.0M)(888.8M)(1.4B)(1.9B)(2.6B)(2.4B)
Accounts Payable8.9M8.9M11.9M11.6M10.7M10.6M
Cash363.8M356.1M393.8M376.7M375.9M376.3M
Other Assets26.3M23.9M33.0M140.8M161.9M170.0M
Other Current Assets22.6M71.3M32.4M59.9M41.0M36.2M
Total Liab155.7M595.7M1.9B1.9B1.9B1.1B
Net Invested Capital500.2M535.2M833.4M453.0M372.5M397.1M
Total Current Assets599.8M642.8M839.7M505.2M477.6M566.9M
Net Working Capital508.2M547.2M709.6M387.4M333.7M469.5M
Common Stock124K125K154K157K181K172.0K
Long Term Debt91.8M475.9M1.7B1.7B1.7B1.1B
Long Term Debt Total91.8M475.9M1.7B1.7B2.0B2.1B
Capital Stock124K125K154K157K181K172.0K

BridgeBio Pharma Key Income Statement Accounts

201920202021202220232024 (projected)
Net Interest Income150K(32.6M)(45.6M)(72.9M)(63.3M)(60.1M)
Interest Income8.9M4.0M1.1M7.5M18.0M18.9M
Interest Expense8.8M36.7M46.8M80.4M81.3M85.4M
Total Revenue40.6M8.2M69.7M77.6M9.3M8.8M
Operating Income(266.2M)(474.5M)(579.7M)(471.9M)(607.4M)(577.0M)
Ebit(266.2M)(468.8M)(539.7M)(404.2M)(572.0M)(543.4M)
Research Development209.9M337.0M454.1M402.9M455.7M319.1M
Ebitda(279.4M)(465.7M)(533.8M)(397.4M)(565.5M)(537.2M)
Income Before Tax(288.6M)(505.5M)(586.5M)(484.7M)(653.3M)(620.6M)
Net Income(260.4M)(483.9M)(639.3M)(494.0M)(643.2M)(611.0M)
Income Tax Expense(28.1M)(21.6M)52.8M9.3M71.5M75.1M
Minority Interest67.5M(56.8M)(23.9M)3.5M10.0M7.6M

BridgeBio Pharma Key Cash Accounts

201920202021202220232024 (projected)
Investments(217.3M)(38.7M)(166.2M)453.1M54.0M56.7M
Change In Cash(72.0M)(5.5M)37.7M20.5M(22.2M)(21.0M)
Net Borrowings36.9M537.0M1.1B(20.5M)(23.6M)(22.4M)
Free Cash Flow(258.7M)(407.2M)(546.2M)(425.8M)(529.0M)(555.5M)
Other Non Cash Items24.5M31.2M18.5M(61.3M)103.9M109.1M
Dividends Paid0.0997K537.0M3.8M4.4M4.2M
Capital Expenditures5.1M7.5M48.2M6.3M1.3M1.2M
Net Income(288.6M)(505.5M)(586.5M)(484.7M)(643.2M)(611.0M)
End Period Cash Flow364.2M358.7M396.4M416.9M394.7M386.5M
Change To Netincome17.9M62.5M111.1M112.7M129.6M136.1M

BridgeBio Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining BridgeBio Pharma's current stock value. Our valuation model uses many indicators to compare BridgeBio Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BridgeBio Pharma competition to find correlations between indicators driving BridgeBio Pharma's intrinsic value. More Info.
BridgeBio Pharma is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, BridgeBio Pharma's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BridgeBio Pharma's earnings, one of the primary drivers of an investment's value.

BridgeBio Pharma Systematic Risk

BridgeBio Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BridgeBio Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on BridgeBio Pharma correlated with the market. If Beta is less than 0 BridgeBio Pharma generally moves in the opposite direction as compared to the market. If BridgeBio Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BridgeBio Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BridgeBio Pharma is generally in the same direction as the market. If Beta > 1 BridgeBio Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in BridgeBio Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BridgeBio Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BridgeBio Pharma growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.54)

At this time, BridgeBio Pharma's Price Earnings To Growth Ratio is very stable compared to the past year.

BridgeBio Pharma December 24, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of BridgeBio Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BridgeBio Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of BridgeBio Pharma based on widely used predictive technical indicators. In general, we focus on analyzing BridgeBio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BridgeBio Pharma's daily price indicators and compare them against related drivers.
When determining whether BridgeBio Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BridgeBio Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bridgebio Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bridgebio Pharma Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.42)
Revenue Per Share
1.194
Quarterly Revenue Growth
(0.33)
Return On Assets
(0.49)
Return On Equity
(17.90)
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.